1. Home
  2. BHVN vs AGIO Comparison

BHVN vs AGIO Comparison

Compare BHVN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$14.53

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$33.61

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHVN
AGIO
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
BHVN
AGIO
Price
$14.53
$33.61
Analyst Decision
Buy
Buy
Analyst Count
14
8
Target Price
$29.08
$38.88
AVG Volume (30 Days)
1.8M
1.2M
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
26.08
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$76.75
Revenue Next Year
N/A
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.48
$22.24
52 Week High
$18.57
$46.00

Technical Indicators

Market Signals
Indicator
BHVN
AGIO
Relative Strength Index (RSI) 52.79 47.68
Support Level $13.84 $26.71
Resistance Level $15.79 $36.07
Average True Range (ATR) 0.65 1.69
MACD 0.04 0.10
Stochastic Oscillator 75.92 64.17

Price Performance

Historical Comparison
BHVN
AGIO

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: